Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib

BACKGROUND: KIT mutations are the predominant driver mutations in gastrointestinal stromal tumors (GISTs), and targeted therapy against KIT has improved treatment outcome dramatically. However, gaining secondary mutation of KIT confers drug resistance of GISTs leading to treatment failure. RESULTS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Guangrong, Shi, Jun, Zhang, Shaoting, Guo, Yue, Huang, Ling, Zhao, Hui, Jiang, Yideng, Sun, Jianmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017564/
https://www.ncbi.nlm.nih.gov/pubmed/32082541
http://dx.doi.org/10.1186/s13578-020-0377-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017564/
https://www.ncbi.nlm.nih.gov/pubmed/32082541
http://dx.doi.org/10.1186/s13578-020-0377-9

Ejemplares similares